Abstract
Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary driver of cervical cancer. These infections are characterized by the high expression of E6 and E7 oncogenes and the absence of capsid proteins. A critical challenge for HPV is its compact 8kb genome, which must encode multiple proteins from polycistronic transcripts. Alternative splicing serves as a vital post-transcriptional mechanism to diversify the viral proteome. This review synthesizes current knowledge on HPV alternative splicing, focusing on the regulatory interplay between host factors and viral proteins, and the functional roles of various splice isoforms in cancer progression.
The Genomic Bottleneck: Why Splicing Matters
Human Papillomavirus (HPV) possesses a remarkably compact double-stranded DNA genome of approximately 8,000 base pairs. Despite its small size, the virus must produce a diverse array of proteins to manage its complex life cycle and, in high-risk types, drive oncogenic transformation.
The primary challenge lies in the polycistronic nature of its mRNAs—a single transcript often contains multiple Open Reading Frames (ORFs). Because eukaryotic ribosomes typically only translate the first ORF they encounter, downstream genes would remain silent without intervention. HPV overcomes this "bottleneck" through alternative splicing, which physically repositions downstream ORFs closer to the 5’ end of the mRNA, enabling their expression.
Mechanisms and Regulation of Alternative Splicing
The diversity of HPV transcripts is achieved through the use of multiple promoters (e.g., p97, p670, pE8) and alternative splice sites. As shown in the transcription map above, a single primary transcript can be processed into numerous isoforms, such as the E6* variants, E1^E4, and E8^E2.
Splicing is governed by a delicate balance between host cell machinery and viral feedback:
- Host Factors: Splicing is regulated by the tug-of-war between host SR proteins (which generally promote splicing) and hnRNPs (which often inhibit it). For instance, hnRNP A1 and A2 act as silencers to prevent the premature expression of late capsid proteins (L1/L2), helping the virus evade the host immune system during early infection.
- Viral Master Regulators: The viral E2 protein acts as a master regulator. High levels of E2 can modulate host splicing factors like SRSF3, effectively controlling the "switch" from early viral replication to the production of late-stage viral particles.
- High-Risk vs. Low-Risk Divergence: A major structural difference between high-risk (HR-HPV) and low-risk (LR-HPV) genotypes is the presence of an intron within the E6 ORF. LR-HPVs (like types 6 and 11) lack this intron and cannot produce E6* isoforms, a factor likely contributing to their lower oncogenic potential.
Functional Roles of Splice Isoforms
The resulting protein isoforms play distinct roles in the viral life cycle and cancer development:
- The E6* "Enabler": E6*I is one of the most studied isoforms. While it is a truncated version of the E6 oncogene, its primary function appears to be facilitating the translation of the E7 oncogene by splicing out the E6 intron, allowing the ribosome to reach the E7 start codon more efficiently.
- Tumorigenic Roles: Beyond E6*I, which can increase reactive oxygen species (ROS) and activate Wnt signaling, other isoforms like E8^E2 contribute to immune escape.
- Late Stage Functions: Isoforms like E1^E4 induce cell cycle arrest, favoring the eventual release of new viral particles.
Future Directions and Clinical Implications
While significant progress has been made in mapping the HPV "interactome," several gaps remain. Research is heavily biased toward HPV16 and HPV18, leaving other high-risk types understudied. Furthermore, the upstream signaling pathways (such as the EGF/Erk1/2 pathway) that trigger changes in splicing behavior during infection are not fully understood.
Understanding these mechanisms offers promising avenues for clinical application. Splicing factors could serve as therapeutic targets to disrupt the viral life cycle. Additionally, specific splice isoforms may eventually be utilized as reliable biomarkers for the early diagnosis and risk stratification of cervical lesions.
Summary updated